Deborah Jalowiec, MD
Cardiovascular Disease · Colorado Springs, CONPI 1205823366
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $88,738 of the $105,905 with a category attached, or 83.8%. Johnson & Johnson accounts for 95.9% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2019 at $35,914 and has fallen 99.9% since, to $23 in 2025. Among cardiovascular disease clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 385 payments — averaging $275.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$102K
- E.r. Squibb & Sons, L.L.C.$889
- Pfizer$548
- Novartis$504
- Amgen$426
- Sanofi-aventis U.S. LLC$359
- plus $2K from 20 others
What the payments were for
- Consulting fees$8001%
- Speaking & faculty fees$88,73884%
- Travel & lodging$9,9819%
- Food & beverage$6,3726%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 176 | $101,583 |
| E.r. Squibb & Sons, L.L.C. | 25 | $889 |
| Pfizer | 33 | $548 |
| Novartis | 29 | $504 |
| Amgen | 24 | $426 |
| Sanofi-aventis U.S. LLC | 19 | $359 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $299 |
| Boehringer Ingelheim | 16 | $245 |
| Merck | 12 | $206 |
| Philips North America LLC | 10 | $201 |
| Edwards Lifesciences | 1 | $151 |
| AstraZeneca | 6 | $85 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $48 |
| Actelion Pharmaceuticals US, Inc. | 2 | $44 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $42 |
| Astellas Pharma US Inc | 3 | $41 |
| Impulse Dynamics (USA) Inc. | 1 | $39 |
| Alnylam Pharmaceuticals Inc. | 2 | $36 |
| Daiichi Sankyo Inc. | 2 | $30 |
| Heartflow, Inc. | 1 | $25 |
| Bardy Diagnostics, Inc. | 1 | $24 |
| Gilead | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $19 |
| Lundbeck LLC | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$98,759
- ELIQUIS$500
- INSPIRIS RESILIA aortic valve$151
How this compares
$105,905 in reported general payments places this provider in the 95th percentile of 276 cardiovascular disease providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 125 | $146,876 |
| EntrestoSacubitril/Valsartan | 66 | $106,881 |
| EliquisApixaban | 74 | $105,489 |
| JardianceEmpagliflozin | 28 | $26,819 |
| Repatha SureclickEvolocumab | 22 | $20,836 |
| Isradipine | 20 | $5,526 |
| Telmisartan | 135 | $5,147 |
| Bisoprolol Fumarate | 121 | $3,795 |
| Rosuvastatin Calcium | 214 | $3,360 |
| Metoprolol Succinate | 199 | $3,119 |
| Nebivolol Hcl | 39 | $2,644 |
| Nifedipine ErNifedipine | 36 | $2,303 |
| Flecainide Acetate | 38 | $1,769 |
| Losartan Potassium | 157 | $1,657 |
| Ranolazine ErRanolazine | 11 | $1,634 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $101,583 | $146,876125 claims |
| NovartisEntresto | $504 | $106,88166 claims |
| PfizerEliquis | $548 | $105,48974 claims |
| Boehringer IngelheimJardiance | $245 | $26,81928 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 276 cardiovascular disease providers in Colorado.
Other cardiovascular disease in Colorado Springs
- Preetham ReddyColorado Springs$9K
- James MillerColorado Springs$6K
- Kimberly DulaneyColorado Springs$6K
- Brian MetzColorado Springs$6K
- Payal KohliAurora$1.7M
- Marc BonacaAurora$703K
- Andrew FreemanDenver$454K
- William SauerAurora$365K
- Jeffrey BooneGreenwood Village$287K
- Rhonda MiyasakaAurora$128K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.